Abstract: We use an individual based model and national level epidemic simulations to estimate the medical costs of keeping the US economy open during COVID-19 pandemic under different counterfactual scenarios. We model an unmitigated scenario and 12 mitigation scenarios which differ in compliance behavior to social distancing strategies and to the duration of the stay-home order. Under each scenario we estimate the number of people who are likely to get infected and require medical attention, hospitalization, and ventilators. Given the per capita medical cost for each of these health states, we compute the total medical costs for each scenario and show the tradeoffs between deaths, costs, infections, compliance and the duration of stay-home order. We also consider the hospital bed capacity of each Hospital Referral Region (HRR) in the US to estimate the deficit in beds each HRR will likely encounter given the demand for hospital beds. We consider a case where HRRs share hospital beds among the neighboring HRRs during a surge in demand beyond the available beds and the impact it has in controlling additional deaths.
Introduction
In early 2020, policymakers faced a critical dilemma: the trade-off between economic activity and public health. While the economic costs of lockdowns were immediately apparent, the medical costs of unmitigated viral spread remained largely unquantified. This study addresses this gap by estimating the direct medical expenses—including outpatient care, hospitalizations, and ventilator use—alongside the economic valuation of mortality across various reopening scenarios.
Methodology
The study utilizes a high-resolution Individual-Based Model (IBM) to simulate the US population. This "digital twin" incorporates demographic data from the US Census and daily activity patterns from the American Time Use Survey. Disease dynamics are governed by a Susceptible-Exposed-Infected-Recovered (SEIR) framework, with parameters calibrated to CDC data.
As shown in Figure 1, infected agents transition through various health states. The model tracks transitions from exposure to infectiousness (symptomatic or asymptomatic) and subsequent medical pathways. Costs were estimated using pneumonia treatment as a proxy for COVID-19 care, and mortality was valued using a $2 million Value of Statistical Life (VSL).
Key Results
The simulations reveal that the total cost of the pandemic is highly sensitive to both the duration of stay-at-home orders and the level of public compliance. In an unmitigated scenario, direct medical costs and mortality losses could exceed $1 trillion, approximately 5% of the US GDP.
Figure 6 illustrates the total costs across different scenarios. A critical finding is the impact of hospital bed sharing. When Hospital Referral Regions (HRRs) operate in isolation ("constrained without sharing"), costs and deaths spike due to capacity deficits. However, sharing resources with neighboring regions ("constrained with sharing") significantly mitigates these losses, bringing outcomes closer to the "unlimited capacity" ideal. High compliance (80-90%) for a duration of 45 to 60 days was found to be the most effective strategy for containing the epidemic and minimizing total costs.
Discussion and Limitations
While the model provides a robust framework for cost estimation, it relies on several assumptions. The use of pneumonia costs may underestimate the actual expense of COVID-19 treatment, which often involves prolonged ICU stays. Furthermore, the model focuses strictly on direct medical costs and mortality, excluding broader economic impacts like productivity loss or long-term disability (Long COVID).
Conclusion
This research underscores that the "cost of doing nothing" far outweighs the medical costs associated with rigorous mitigation. Strategic resource sharing between hospital regions and maintaining high compliance for at least 45 days are essential components of an economically and medically sound pandemic response.
Reference: Chen, J., et al. (2020). Medical Costs of Keeping the US Economy Open During COVID-19. medRxiv preprint.
Summary updated